Leerink Partnrs Has Positive Outlook of CorMedix Q4 Earnings

CorMedix Inc (NASDAQ:CRMD) – Stock analysts at Leerink Partnrs boosted their Q4 2025 EPS estimates for shares of CorMedix in a note issued to investors on Monday, November 17th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn $0.92 per share for the quarter, up from their prior forecast of $0.75. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix’s FY2027 earnings at $3.28 EPS.

Several other research firms have also weighed in on CRMD. Needham & Company LLC lowered their price objective on shares of CorMedix from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, November 12th. Weiss Ratings reissued a “hold (c)” rating on shares of CorMedix in a research report on Wednesday, October 8th. Wall Street Zen lowered CorMedix from a “buy” rating to a “hold” rating in a research note on Saturday. Royal Bank Of Canada reiterated an “outperform” rating and set a $22.00 target price (up from $21.00) on shares of CorMedix in a research note on Tuesday, October 21st. Finally, D. Boral Capital reissued a “buy” rating and set a $14.00 target price on shares of CorMedix in a report on Wednesday, November 12th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $18.33.

CorMedix Trading Up 0.9%

NASDAQ:CRMD opened at $10.07 on Wednesday. The stock has a market capitalization of $793.41 million, a PE ratio of 13.43 and a beta of 1.80. CorMedix has a 1-year low of $5.60 and a 1-year high of $17.43. The firm has a fifty day simple moving average of $11.27 and a 200 day simple moving average of $12.11.

CorMedix (NASDAQ:CRMD) last released its earnings results on Wednesday, November 12th. The company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.78. CorMedix had a return on equity of 42.73% and a net margin of 42.11%.The business had revenue of $104.28 million for the quarter, compared to the consensus estimate of $65.63 million. During the same quarter in the previous year, the business earned ($0.05) earnings per share. CorMedix’s quarterly revenue was up 810.2% on a year-over-year basis. CorMedix has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Insider Buying and Selling at CorMedix

In related news, COO Elizabeth Hurlburt sold 41,121 shares of the business’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $13.08, for a total value of $537,862.68. Following the completion of the sale, the chief operating officer directly owned 176,990 shares in the company, valued at $2,315,029.20. The trade was a 18.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kaufman Beth Zelnick sold 50,000 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $13.41, for a total value of $670,500.00. Following the transaction, the insider owned 180,418 shares in the company, valued at $2,419,405.38. The trade was a 21.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 163,997 shares of company stock worth $2,163,617 in the last 90 days. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of CorMedix by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,646,551 shares of the company’s stock valued at $22,463,000 after buying an additional 268,360 shares during the period. Marshall Wace LLP raised its holdings in CorMedix by 34.6% in the 3rd quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock valued at $40,397,000 after acquiring an additional 893,518 shares in the last quarter. Deerfield Management Company L.P. bought a new stake in shares of CorMedix during the 3rd quarter valued at $38,656,000. Geode Capital Management LLC grew its holdings in shares of CorMedix by 11.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,596,322 shares of the company’s stock worth $19,669,000 after purchasing an additional 163,403 shares in the last quarter. Finally, Alyeska Investment Group L.P. increased its position in shares of CorMedix by 68.4% in the third quarter. Alyeska Investment Group L.P. now owns 1,262,979 shares of the company’s stock worth $14,688,000 after purchasing an additional 512,979 shares during the period. Institutional investors and hedge funds own 34.18% of the company’s stock.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.